 Oragenics, Inc. is a small development-stage biotechnology company developing novel therapeuticsantibiotics for infectious diseases, particularly COVID-19 and C. difficile. Oragenics is developing two pre-IND candidates for infectious diseases which aim to both submit INDs in 4Q 2021 with their lead candidate as Terra CoV-2, a differentiated pre-fusion targeting vaccine. 